CLDN18 and gastroesophageal junction adenocarcinoma: Recently, the phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) studies demonstrated statistically significant improvements in progression-free survival (PFS) and OS when zolbetuximab was combined with chemotherapy in patients with HER2-negative, LA unresectable or mG/GEJ adenocarcinoma whose tumors were CLDN18.2-positive [26, 27].